A biobank of 256 patient-derived tumour organoids reveals diverse gene dependencies across multiple cancer types, advancing precision oncology.
- 3 cited this week
- Open access
Moving in Nature, Cancer Cell and The Lancet Oncology.
Rebuilt
A biobank of 256 patient-derived tumour organoids reveals diverse gene dependencies across multiple cancer types, advancing precision oncology.
A large-scale international effort created 665 next-generation patient-derived cancer models with 97.8% genetic and 95% epigenetic fidelity to original tumors, covering 25 cancer types.
Spatial multi-omics reveals that liver micrometastases in colorectal cancer originate early and exhibit dormancy, with a six-gene signature linked to disease recurrence and therapy resistance.
Access to cancer genomics and precision oncology remains profoundly unequal across and within countries, leaving millions without guideline-indicated interventions annually.
Newest first · last 60 days
Recurrent genomic driver alterations are identified in 97% of primary prostate tumors, revealing four distinct oncotypes with varying clinical outcomes.
AmpliconSuite accurately predicts ecDNA and amplification modes in 72 models and reveals ecDNA-mediated oncogene co-amplification in 6,506 pan-cancer samples.
Partial preservation of cfDNA fragmentomic signals in methylation sequencing enables effective cancer detection models with the strongest performance from genome-wide integration.
Nanopore sequencing with SomaGauss-SV detects high-frequency somatic structural variations in 71.79% of LSCC patients, revealing recurrent genomic alterations.
Mapping significantly mutated regions to protein domains and structural features creates a proteo-genomics framework for interpreting cancer mutations beyond genes and hotspots.
Micronuclear ecDNA formation under replication stress reduces tumor cell fitness and is linked to improved survival in MYCN-amplified neuroblastoma patients.
A gene-centered framework reveals context-dependent shifts in DNA methylation biomarker candidates across multiple cancers.
Punctuated mutagenesis significantly enhances tumor cells' ability to cross fitness valleys, promoting multi-step adaptation in human cancers.
SPOP-mutant prostate cancer exhibits Wnt pathway dysregulation and diverse transcriptional signatures across racial groups, with 40 tumors analyzed for genomic and transcriptomic features.
Multimodal biomarkers combining liquid biopsy, AI-based imaging, and tumor immune profiling may improve early detection and immunotherapy assessment in hepatocellular carcinoma.
Cancer cells from five different organs show a fourfold increase in mutational burden compared to normal cells, highlighting a significant difference in mutation accumulation.
Biologically informed machine learning enables stage-aware genomic risk stratification in prostate cancer, integrating inherited susceptibility and tumor biology.
The multi-cancer early detection (MCED) test in the PATHFINDER 2 study achieved a cancer detection rate of 0.54% among participants aged 50 or older, with a CSO prediction accuracy of 91.3%.
Multimodal lineage tracing combined with deep learning enhances the accuracy of cell fate and trajectory analysis in single-cell multi-omic data.
DePass achieves superior integration accuracy across 6 modalities, 9 tissue types, and 13 platforms in single-cell and spatial multi-omics data.
A blood-based microRNA assay combined with carbohydrate antigen 19-9 detects early-stage pancreatic ductal adenocarcinoma with 86.8% sensitivity in a large international study.
Journals this month
Topics moving, week to 22 Oct 2026